Literature DB >> 25850040

Pfizer's CDK4/6 inhibitor approved for advanced breast cancer.

Chris Morrison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25850040     DOI： 10.1038/nbt0415-323

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Blockbuster dreams for Pfizer's CDK inhibitor.

Authors:  Malini Guha
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908
  1 in total
  3 in total

1.  Astex shapes CDK4/6 inhibitor for approval.

Authors:  Mark Peplow
Journal:  Nat Biotechnol       Date:  2017-05-09       Impact factor: 54.908

Review 2.  Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

Authors:  Libero Santarpia; Giulia Bottai; Catherine M Kelly; Balázs Győrffy; Borbala Székely; Lajos Pusztai
Journal:  Oncologist       Date:  2016-07-06

Review 3.  Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer.

Authors:  Aditi S Khatpe; Adedeji K Adebayo; Christopher A Herodotou; Brijesh Kumar; Harikrishna Nakshatri
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.